Media & Investor Relations:
Troy Wichterman
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com
Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.
Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Dec 02 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Nov 12 2019Global leader in liquid nitrogen storage systems expected to support growth, diversify revenue and reduce evo® manufacturing costs
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Nov 12 2019Third quarter revenue of $6.6 million, up 25% over the prior year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Nov 07 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that based on revenue...
- Oct 31 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the...
- Oct 14 2019Intellectual Property Portfolio Growing with Inventions by Acquired Companies
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced three new patents for inventions related...
- Sep 24 2019BioLife's strategic acquisition strategy expanded to include co-investment with Casdin Capital to boost early stage company development and commercialization
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced a co-investment accelerator program with...
- Sep 16 2019Leading Cell and Gene Therapy Companies are De-Risking Clinical Trial and Commercial Shipments by Using State of the Art Cloud-Connected Shippers and evo.is
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced several new customers have...
- Sep 03 2019Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that Mustang Bio, Inc....
- Aug 28 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the hiring of two key...
- Aug 12 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today...
- Aug 08 2019- Record quarterly revenue of $6.7 million, up 29% over the prior year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Aug 08 2019evo® Cold Chain Management System, Designed for High-Value, Temperature-Sensitive Biologics, Used for Initial Shipments by 50 Cell & Gene Therapy Companies
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a...
- Jul 31 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Jul 30 2019Reduced in-transit shipping damage, Extended dynamic thermal performance and Predictive Analytics in Next Generation Dry Vapor Liquid Nitrogen Shippers
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a...
- Jul 23 2019evo® Cold Chain Management System and LifeGuard Same Day Service Reduce Risks for High-Value, Temperature-Sensitive Biologic Drugs
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a...
- Jul 08 2019Acquisition further strengthens portfolio of best in class, proprietary enabling solutions for cell and gene therapy companies
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies,...
- Jun 10 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 30 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 29 2019Cloud-Connected, Smart Shippers and evo.is Real-Time Visibility Platform Improve Quality of Transportation and Delivery of Lifesaving Therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 09 2019- Revenue Increased 51% to a Record $5.8 million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices...
- May 02 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Apr 02 2019Gains products that automate the thawing process for high-value biologic therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has closed the previously announced transaction for the acquisition of Astero Bio Corporation ("Astero"), an innovator in...
- Mar 14 2019Revenue Increased 79% for the Year to $19.7 Million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Mar 14 2019Gains products that automate the thawing process for high-value biologic therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has entered into an agreement to acquire Astero Bio Corporation ("Astero"), a privately-held innovator in the design,...
- Mar 04 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Feb 19 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that...
- Jan 22 2019FDA Cites Increases in IND Submissions and Anticipated Product Approvals that could benefit BioLife Solutions
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, expects to benefit from new...
- Nov 27 2018Redemption eliminates annual cash dividend payment
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, ("BioLife" or the "Company"),...
- Nov 13 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that...
- Nov 08 2018Revenue increases 79% to a record $5.3 million; achieves net income of $1.2 million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today reported...
- Nov 01 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the...
- Oct 01 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Sep 05 2018Agreement Includes 18-Month Option to Acquire all SAVSU Outstanding Shares
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that it has increased its...
- Aug 22 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that CEO Mike Rice, accompanied...
- Aug 09 2018Revenue increases 102% to $5.2 million. Net income of $1.0 million achieved
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Aug 09 2018M&A Activities to Focus on Cell and Gene Manufacturing Tools
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that...
- Aug 06 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that...
- Aug 02 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the...
- Jul 09 2018Investment Firm to Purchase Shares from Existing Holders
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that two...
- Jul 02 2018Full Year 2018 Revenue Guidance Increased
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Jun 11 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, today announced that it is set to join the Russell...
- May 29 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, today announced Michael Rice, CEO, and Roderick de...
- May 17 2018Redemption reduces annual cash dividend payment by $106,000
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, ("BioLife" or the "Company"), today announced it has...
- May 16 2018SAVSU Realizing Expanded evo® Product Adoption by Leading Specialty Logistics Providers and Cell Therapy Manufacturers
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, ("BioLife" or the "Company"), today announced a $1...
- May 10 201861% Revenue Growth at $3.8 Million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- May 03 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the...
- Apr 30 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Apr 09 2018Investment Firm to Purchase Shares from Existing Holder
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that...
- Apr 02 20182018 Revenue Guidance Revised Upward
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...